Exploration in the Therapeutic and Multi-Target Mechanism of Ketamine on Cerebral Ischemia Based on Network Pharmacology and Molecular Docking
Li Xiong,Shi-Cheng Liu,Si-Ying Huo,Lan-Qing Pu,Jun-Jie Li,Wen-Ya Bai,Yuan Yang,Jian-Lin Shao
DOI: https://doi.org/10.2147/IJGM.S345884
IF: 2.145
2022-04-20
International Journal of General Medicine
Abstract:Li Xiong, 1, &ast Shi-Cheng Liu, 2, &ast Si-Ying Huo, 1 Lan-Qing Pu, 1 Jun-Jie Li, 1 Wen-Ya Bai, 1 Yuan Yang, 1 Jian-Lin Shao 1 1 Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, People's Republic of China; 2 Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jian-Lin Shao, Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan, 650032, People's Republic of China, Email Background: Ketamine is famous for its dissociative anesthetic properties. It is also analgesic, anti-inflammatory and anti-depressant, and even has a cerebral protective effect. We searched the evidence of the correlation between ketamine target and clinical efficacy and utilized network pharmacology to gather information about the multi-target mechanism of ketamine against cerebral ischemia (CI). We found that ketamine's clinical significance may be more extensive than previously thought. Methods: The drug target of ketamine and CI-related genes were predicted by SwissTargetPrediction, DrugBank, PubChem, GeneCards and DisGeNET databases. The intersection of ketamine's drug-targets and CI-related genes was analyzed by using GO and KEGG. We predicted the molecular docking between the potential target and ketamine. Results: The results indicated that the effect of ketamine on CI was primarily associated with the target of α-synuclein (SNCA), muscarinic acetylcholine receptor M1 (CHRM1) and nitric oxide synthase 1 (NOS1). It principally regulates the signal pathways of circadian transmission, calcium signaling pathway, dopaminergic synapse, cholinergic synapse and glutamatergic synapse. Molecular docking analysis exhibited that hydrogen bond and Pi-Pi interaction were the predominant modes of interaction. Conclusion: There are protein targets affected by ketamine in the treatment of CI. Three pivotal targets involving 298 proteins, SNCA, CHRM1 and NOS1, have emerged as multi-target mechanisms for ketamine in CI therapy. Similarly, this study also provides a new idea for introducing network pharmacology into the evaluation of multi-targeted drugs for CI and cerebral protection. Keywords: ketamine, cerebral ischemia, treatment target, network pharmacology Cerebral ischemia (CI) is a widespread acute cerebrovascular disease, which is the second leading cause of death in the world, 1 and China has the highest burden of stroke in the world. 2 Ischemic stroke is characterized by high incidence rate, high disability rate and high mortality rate. 3,4 The critical aspect of treatment is to reduce or prevent the nerve injury caused by CI. 5,6 The neuroprotective effects of CI have been studied for more than half a century, especially in the past 30 years. 7,8 Nevertheless, the really effective method is still under exploration. Therefore, it is imperative to seek new treatment methods. Ketamine is a classic intravenous anesthetic. Its anesthetic and analgesic properties are typically attributed to its direct inhibition of N-methyl-D-aspartate receptor (NMDAR). 9 Not only that but it also has affinity for many other receptors, including γ-aminobutyric acid, dopamine, serotonin, opioid and cholinergic receptors, as well as voltage-gated sodium and hyperpolarized cyclic nucleotide gated channels. Hence, its clinical significance may be broader than previously thought. 10,11 In recent years, ketamine has made significant breakthroughs as an antidepressant. 12,13 In the treatment of CI, although previous studies have demonstrated that ketamine can ameliorate the behavioral and neuroprotective effects on animal models. 14 It may be achieved by affecting the NF-κB signaling pathway, reducing TNF-α, IL-6 and increasing the content of IL-10. 15 It may also activate mTOR signal transduction pathway through p-mTOR and down-regulate the expression of key autophagic proteins (such as LC3 and beclin-1), while attenuating secondary brain injury and reducing inflammatory response. 16 Nevertheless, the precise mechanism of ketamine for CI is not known. Along with the rapid development of bioinformatics, systems biology and pharmacology, web-based drug discovery and evaluation databases are considered to be an effective and cost-effective method for drug development. 17,18 The combination of online pharmacology and bioinformatics tools has broa -Abstract Truncated-
medicine, general & internal